Please login to the form below

Not currently logged in
Email:
Password:

Synairgen

This page shows the latest Synairgen news and features for those working in and with pharma, biotech and healthcare.

AZ severe asthma drug benralizumab backed by CHMP

AZ severe asthma drug benralizumab backed by CHMP

Last year AZ's respiratory pipeline suffered another setback after the company halted a phase IIa trial of a Synairgen-partnered inhaled interferon beta formulation (AZD9412) for asthma, deciding it was

Latest news

  • Setback for AZ as tralokinumab flunks asthma trial Setback for AZ as tralokinumab flunks asthma trial

    Last year AZ's respiratory pipeline suffered another setback after the company halted a phase IIa trial of a Synairgen-partnered inhaled interferon beta formulation (AZD9412) for asthma, deciding it was

  • AZ trial adds to pessimism about anti-IL-13 asthma drugs AZ trial adds to pessimism about anti-IL-13 asthma drugs

    Last year AZ's respiratory pipeline took a further knock when it halted a phase IIa trial of a Synairgen-partnered inhaled interferon beta formulation (AZD9412) for asthma after deciding it

  • Synairgen sinks as AZ halts trial of asthma drug Synairgen sinks as AZ halts trial of asthma drug

    Synairgen sinks as AZ halts trial of asthma drug. Results from a phase II trial of inhaled antiviral therapy set to be inconclusive. ... AZD9412 is an inhaled form of interferon beta partnered with UK company Synairgen, which saw its London Stock Exchange

  • AZ licenses asthma infection drug from Synairgen AZ licenses asthma infection drug from Synairgen

    AZ licenses asthma infection drug from Synairgen. Boosts respiratory portfolio with $232m deal. ... AstraZeneca (AZ) has added to its portfolio of respiratory drug candidates after licensing an inhaled interferon beta therapy from Synairgen which is in

  • Pharma continues to attract investors

    Synairgen raises fresh cash for asthma and pulmonary disease research. Synairgen, the drug research company, rose just over 1p to 19p following a share placing at 17p to raise £6.35m – ... The cash produced by the discounted placing is to go towards

More from news
Approximately 2 fully matching, plus 4 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health Media

Four Health Media creates world class integrated media solutions with global reach, deep insight, innovative methods and a highly personal...

Latest intelligence

No Voice, No Choice
Adelphi Research UK’s insights help to campaign for change in the Mental Health Act...
Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...

Infographics